On February 10, 2026, Psyence Biomedical Ltd. approved a share exchange with Psyence Labs Ltd., involving a subscription of $5 million. This exchange is expected to complete by February 25, 2026, giving PsyLabs approximately 49.98% ownership in Psyence.